Medtronic Recently Received FDA Approval of Updated Labeling for DBS for Parkinsonís Disease


Medtronic recently received FDA approval of updated labeling for DBS for Parkinson’s disease, supporting the growing evidence that Medtronic DBS Therapy, in addition to medication, is associated with benefits over time. These benefits include quality of life/motor function improvements, significantly reduced medication use, and long-term safety and effectiveness. Read more…

Click for a printer friendly version

Back to top